01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Biological preparations, other than for medical or veterinary purposes; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; diagnostic preparations for research laboratory use; diagnostic preparations, other than for medical or veterinary purposes. Chemico-pharmaceutical preparations; diagnostic biomarker reagents for medical purposes; diagnostic preparations for medical purposes; diagnostic preparations for medical purposes used by medical laboratories; diagnostic preparations for veterinary purposes; pharmaceutical preparations; pharmaceuticals; biological preparations for medical purposes; biological preparations for veterinary purposes; chemical preparations for medical purposes; chemical preparations for pharmaceutical purposes; chemical preparations for veterinary purposes; chemical reagents for medical or veterinary purposes. Computer programs, downloadable; computer programs, recorded; computer software applications, downloadable; computer software platforms, recorded or downloadable; computer software, recorded; diagnostic apparatus for research laboratory use; diagnostic apparatus, not for medical purposes; interfaces for computers; laboratory robots; material testing instruments and machines; test tubes; testing apparatus not for medical purposes. Apparatus for DNA and RNA testing for medical purposes; blood testing apparatus; diagnostic apparatus for medical purposes; diagnostic apparatus for medical purposes used in medical laboratories; medical apparatus and instruments; surgical apparatus and instruments; testing apparatus for medical purposes; analysers for bacterial identification for medical purposes.
2.
FUSION PROTEINS COMPRISING SARS-COV-2 SPIKE PROTEIN OR THE RECEPTOR THEREOF
A fusion protein containing the full length SARS-CoV-2 spike protein, or the S1 domain or the S2 domain of the SARS-CoV-2 spike protein or a fragment, or the human Angiotensin Converting Enzyme 2 (ACE2) receptor of the SARS-CoV-2 spike protein or a fragment, and a N-terminal signal peptide, and at least one of the following: a polyhistidine tag, a streptavidin binding domain, a linker, or an oligomerization tag.
The present invention relates to a method for detecting at least one target nucleic acid sequence from a nucleic acid mixture by a double quenched assay. The double quenched assay of the method exploits a novel approach for melting temperature mediated identification of multiple target nucleic acid sequences. The invention further relates to a kit of parts.
The present invention relates to a method for detecting at least one target nucleic acid sequence from a nucleic acid mixture by a double quenched assay. The double quenched assay of the method exploits a novel approach for melting temperature mediated identification of multiple target nucleic acid sequences. The invention further relates to a kit of parts.
A fusion protein includes the SARS-COV-2 receptor binding domain (RBD) of the SARS-COV-2 spike protein or a fragment, and a N-terminal signal peptide, and at least one of the following: a polyhistidine tag, linker, an oligomerization tag, a region in spike protein outside RBD, a horseradish peroxidase binding domain or a protease cleavage site.
An anti-HIV-1 antibody comprising L-CDR1, L-CDR2 and L-CDR3, wherein L-CDR1 is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, and a sequence that differs from anyone of SEQ ID NOs: 15, 18, or 21 by one or two substitutions, deletions, or additions, the amino acid sequence of L-CDR2 is selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, and a sequence that differs from anyone of SEQ ID NOs: 16, 19, or 22 by one or two substitutions, deletions, or additions, and the amino acid sequence of L-CDR3 is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, and a sequence that differs from anyone of SEQ ID NOs: 17, 20, or 23 by one or two substitutions, deletions, or additions.
A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
8.
COMPOSITIONS AND METHODS FOR STORING A BIOLOGICAL SAMPLE
Aqueous compositions are for storing a biological sample for subsequent nucleic acid testing. The compositions include a first component, which includes an anionic detergent in an amount from about 1% to 20% (w/v), a Group I metal hydroxide in an amount from about 1% to 5% (w/v), a chelating agent in an amount from about 0.5% to 5% (w/v), and a first buffer. The composition further includes a diluting component selected from water, a second buffer, a Transport Medium, Sodium Chloride (aq), and combinations. The first component can be diluted up to a maximum of about 50% (v/v) with the diluting component.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state
9.
IMMUNOASSAYS AND ENGINEERED PROTEINS FOR MONITORING ANTIBODY TREATMENTS TO THE IMMUNE CHECKPOINT INHIBITORS PD1 AND PD-L1
Fusion proteins include an extracellular domain of PD1 protein (programmed cell death protein-1) and/or an extracellular domain of PD-L1 protein (programmed cell death-ligand 1 protein (CD274 or B7-H1)). Portions of the extracellular domains are expressed in specific configurations and purified as protein, which are used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. A method is for determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient when the patient has undergone at least one dose of immunotherapy.
A composition that binds to an anti-CD47 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD47 and/or a fragment thereof that interferes with binding activity of the anti-CD47 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD47 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD47 antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
11.
Methods and Compositions for Treating Aging-Associated Impairments with TIMP-2 Recombinant Proteins
Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include recombinant protein constructs employing human TIMP-2 protein for use in treating indications related to aging-related cognitive impairment.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
12.
METHODS AND COMPOSITIONS FOR TREATING AGING-ASSOCIATED IMPAIRMENTS WITH TIMP-2 RECOMBINANT PROTEINS
Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include recombinant protein constructs employing human TIMP-2 protein for use in treating indications related to aging-related cognitive impairment.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A fusion protein includes a SARS-CoV-2 nucleocapsid N-terminal domain and/or a SARS-CoV-2 nucleocapsid C-terminal domain, wherein the fusion protein lacks the SARS-CoV-2 nucleocapsid aggregation domain.
The medical field of COVID-19 diagnosis relates to methods for detecting SARS-CoV-2 nucleic acids in a sample as well as combinations of oligomers for determining the presence or absence of SARS-CoV-2 in a Sample.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
15.
COMPOSITIONS AND METHODS FOR STORING A BIOLOGICAL SAMPLE
The present invention refers to aqueous compositions for storing a biological sample for subsequent nucleic acid testing, the compositions comprising a first component comprising: i) an anionic detergent in an amount from about 1 % to 20 % (w/v), ii) a Group I metal hydroxide in an amount from about 1 % to 5% (w/v), iii) a chelating agent in an amount from about 0.5 % to 5 % (w/v), and iv) a first buffer, wherein the composition further comprises a diluting component selected from the group consisting of water, a second buffer, a Transport Medium, Sodium Chloride (aq), and combinations thereof, wherein the first component is diluted up to a maximum of about 50 % (v/v) with the diluting component.
Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and capture probes, for detection of Plasmodium species nucleic acid in a sample. Also disclosed are methods of specific nucleic acid amplification and detection, including amplification and detection of target nucleic acid in real time, using the disclosed oligomers, as well as corresponding reaction
C12Q 1/6893 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
A device for breaking cells that has a reactor with a reaction chamber, an agitator, a cooling jacket, a cooling jacket inlet, a cooling jacket outlet, a sampling port, and a temperature probe insertion fitting, and a motor suitable for mounting the reactor on its top and which is operably connected with the agitator. A system for breaking cells comprising at least one device, at least one temperature probe inserted in the temperature probe insertion fitting of the device, a cooling system operably connected to the temperature probe, and an electronic control panel. The cooling system has at least one solenoid valve, each device of the system having one corresponding solenoid valve.
The present invention refers to fusion proteins comprising a SARS-CoV-2 nucleocapsid N-terminal domain and/or a SARS-CoV-2 nucleocapsid C-terminal domain, wherein said fusion protein lacks the SARS-CoV-2 nucleocapsid aggregation domain.
A fusion protein comprising the SARS-CoV-2 receptor binding domain (RBD) of the SARS-CoV-2 spike protein or a fragment thereof, and a N-terminal signal peptide, and at least one of a polyhistidine tag, linker, an oligomerization tag, a region in spike protein outside RBD, a horseradish peroxidase binding domain or a protease cleavage site.
A fusion protein comprising the full length SARS-CoV-2 spike protein, or the S1 domain or the S2 domain of the SARS-CoV-2 spike protein or a fragment thereof, or the human Angiotensin Converting Enzyme 2 (ACE2) receptor of the SARS-CoV-2 spike protein or a fragment thereof, and a N-terminal signal peptide, and at least one of a polyhistidine tag, a streptavidin binding domain, a linker, or an oligomerization tag.
An anti-HIV-1 antibody comprising L-CDR1, L-CDR2 and L-CDR3, wherein L-CDR1 is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, and a sequence that differs from anyone of SEQ ID NOs: 15, 18, or 21 by one or two substitutions, deletions, or additions, the amino acid sequence of L-CDR2 is selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, and a sequence that differs from anyone of SEQ ID NOs: 16, 19, or 22 by one or two substitutions, deletions, or additions, and the amino acid sequence of L-CDR3 is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, and a sequence that differs from anyone of SEQ ID NOs: 17, 20, or 23 by one or two substitutions, deletions, or additions.
An anti-HIV-1 antibody comprising L-CDR1, L-CDR2 and L-CDR3, wherein L-CDR1 is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, and a sequence that differs from anyone of SEQ ID NOs: 15, 18, or 21 by one or two substitutions, deletions, or additions, the amino acid sequence of L-CDR2 is selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, and a sequence that differs from anyone of SEQ ID NOs: 16, 19, or 22 by one or two substitutions, deletions, or additions, and the amino acid sequence of L-CDR3 is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, and a sequence that differs from anyone of SEQ ID NOs: 17, 20, or 23 by one or two substitutions, deletions, or additions.
A device for determining a cellular-bound analyte in a liquid sample includes a separation matrix with at least one indicator zone. The indicator zone includes a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody. The first antibody is an incomplete antibody. The separation matrix can be designed in the form of the membrane of a lateral flow assay device or as a gel matrix. For example, the device can include a membrane with a charging zone for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region, which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone and the absorption region. The indicator zone can include an antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody.
G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody
G01N 33/559 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody through a gel, e.g. Ouchterlony technique
24.
SYSTEMS AND METHODS FOR BIOLOGICAL SAMPLE LABORATORY SCREENING
Systems and methods for guiding the management of blood/plasma screening laboratory workflow are disclosed. A system for analyzing biological samples can include centrifuges, pooling devices, biological sample analyzing devices, and a processor to monitor operation of the centrifuges, the pooling devices, and the biological sample analyzing devices. The processor can track the progress of the biological samples and generate progress indications In response to determining that an external control is present, the system can prevent release of the biological component to the biological sample analyzing device until the external control is also loaded into the analyzer. In response to a component of a biological sample being grouped into more than one pool or not intended to be pooled, the system can generate a warning. The system can provide a chronology of states, display the status of instruments/biological samples, indicate what components need operator attention, and search the status of samples/tests.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
25.
METHODS AND COMPOSITIONS FOR DETECTING SARS-COV-2 NUCLEIC ACID
This application relates to the medical field of COVID-19 diagnosis, and in particular, it relates to methods for detecting SARS-CoV-2 nucleic acids in a sample. This application also relates to combinations of oligomers for determining the presence or absence of SARS-CoV-2 in a Sample.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
26.
ANTI D-DIMER RECOMBINANT ANTIBODIES, METHODS AND USES THEREOF
This application relates to anti-D-Dimer recombinant antibodies that specifically bind to fibrin and fibrinogen degradation products (FDP) such as D-Dimer, fragment DD and fragment D with high binding affinity and do not bind to fragment E and fibrinogen. The present invention also refers to methods and assays for detection of D-Dimer and FDP fragments in samples using said recombinant antibodies.
A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
28.
DUAL QUENCHING ASSAY FOR MULTIPLEX DETECTION OF TARGET NUCLEIC ACIDS
The present invention relates to a method for detecting at least one target nucleic acid sequence from a nucleic acid mixture by a double quenched assay. The double quenched assay of the method exploits a novel approach for melting temperature mediated identification of multiple target nucleic acid sequences. The invention further relates to a kit of parts.
Novel mammalian expressed human immunodeficiency virus envelope Protein antigens Various embodiments of the invention relate to polypeptides comprising 1-10 or more epitopes of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks the transmembrane domain of the HIV gp41 protein. Such polypeptides may be expressed in mammalian cells, such as human cells, to produce, for example, polypeptides that are useful in developing novel anti-HIV antibodies. Polypeptides described herein and novel antibodies developed therefrom are generally useful for medical diagnostics, and they may also be useful in the prophylactic and therapeutic treatment of HIV.
Various aspects of the invention relate to compositions and methods of analyzing blood plasma, blood serum, and manufacturing pools of plasma-derived products wherein an anionic surfactant is added to an aliquot of the blood plasma, blood serum, or manufacturing pool prior to analysis, and the counterion of the anionic surfactant is not sodium ion. The anionic surfactant may be, for example, lauryl sulfate. The counterion of the anionic surfactant may be, for example, lithium ion.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
40 - Treatment of materials; recycling, air and water treatment,
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Custom manufacture of pharmaceutical, veterinary and diagnostic preparations and substances; custom manufacture of biopharmaceuticals; biomanufacturing for others, namely, processing of biopharmaceutical materials for others; consultancy services relating to manufacturing processes for pharmaceutical, veterinary and diagnostic substances; custom manufacture of recombinant proteins Chemical preparations for use in industry; chemicals used in science; reagents for scientific purposes; diagnostic preparations, namely, antigens and antibodies for scientific purposes; testing kits for scientific purposes predominantly consisting of reagents; proteins for industrial use, namely, antigens and antibodies; nucleic acids for laboratory use, namely, nucleic acid for the production of proteins produced by biochemical and/or genetic engineering methods Antibacterial pharmaceuticals; diagnostic veterinary preparations; diagnostic preparations for medical purposes; diagnostic preparations, namely, antigens and antibodies for medical purposes for use in disease testing; pharmaceutical, veterinary and/or diagnostic preparations and substances produced by biochemical and/or genetic engineering methods, namely, antivirals and diagnostic preparations for veterinary and medical use; reagents for medical purposes; tests and test kits for medical and pharmaceutical purposes, namely, drug testing kits comprised of medical diagnostic reagents and assays that testing bodily fluids Scientific and technological services, namely, pharmaceutical and new product research and design; scientific research and development services; research in the chemical, medical, and/or biochemical field; development of pharmaceutical, veterinary medicine and medical diagnostic substances and products and pharmaceutical research regarding methods for the manufacture thereof, namely, using biotechnological and genetically-engineered means; process development services in relation to pharmaceutical, veterinary and diagnostic substances, namely, consulting regarding the development of pharmaceutical preparations and medicines; technical consultancy in the pharmaceutical, veterinary and diagnostic sector, namely, technical consulting in the field of pharmaceutical studies; new product development services in relation to recombinant protein technology and development
40 - Treatment of materials; recycling, air and water treatment,
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Custom manufacture of pharmaceutical, veterinary and diagnostic preparations and substances; custom manufacture of biopharmaceuticals; biomanufacturing for others, namely, processing of biopharmaceutical materials for others; consultancy services relating to manufacturing processes for pharmaceutical, veterinary and diagnostic substances; custom manufacture of recombinant proteins Chemical preparations for use in industry; chemicals used in science; reagents for scientific purposes; diagnostic preparations, namely, antigens and antibodies for scientific purposes; testing kits for scientific purposes predominantly consisting of reagents; proteins for industrial use, namely, antigens and antibodies; nucleic acids for laboratory use, namely, nucleic acid for the production of proteins produced by biochemical and/or genetic engineering methods Antibacterial pharmaceuticals; diagnostic veterinary preparations; diagnostic preparations for medical purposes; diagnostic preparations, namely, antigens and antibodies for medical purposes for use in disease testing; pharmaceutical, veterinary and/or diagnostic preparations and substances produced by biochemical and/or genetic engineering methods, namely, antivirals and diagnostic preparations for veterinary and medical use; reagents for medical purposes; tests and test kits for medical and pharmaceutical purposes, namely, drug testing kits comprised of medical diagnostic reagents and assays that testing bodily fluids Scientific and technological services, namely, pharmaceutical and new product research and design; scientific research and development services; research in the chemical, medical, and/or biochemical field; development of pharmaceutical, veterinary medicine and medical diagnostic substances and products and pharmaceutical research regarding methods for the manufacture thereof, namely, using biotechnological and genetically-engineered means; process development services in relation to pharmaceutical, veterinary and diagnostic substances, namely, consulting regarding the development of pharmaceutical preparations and medicines; technical consultancy in the pharmaceutical, veterinary and diagnostic sector, namely, technical consulting in the field of pharmaceutical studies; new product development services in relation to recombinant protein technology and development
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical preparations for use in industry; chemicals used in science; reagents for scientific purposes; diagnostics, in particular antigens and antibodies, for scientific purposes; testing kits for scientific purposes, predominantly consisting of reagents; proteins, in particular antigens and antibodies; nucleic acids, in particular for the production of proteins produced by biochemical and/or genetic engineering methods. Pharmaceuticals; veterinary preparations; preparations for medical purposes; diagnostics, in particular antigens and antibodies, for medical purposes; pharmaceutical, veterinary and/or diagnostic preparations and substances produced by biochemical and/or genetic engineering methods; reagents for medical purposes; tests and test kits for medical and pharmaceutical purposes. Custom manufacture of pharmaceutical, veterinary and diagnostic preparations and substances; custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; consultancy services relating to manufacturing processes for pharmaceutical, veterinary and diagnostic substances; custom manufacture of recombinant proteins. Scientific and technological services and research and design relating thereto; scientific research and development services; research in the chemical, medical, and/or biochemical field; development of pharmaceutical, veterinary and diagnostic substances and products, and methods for the manufacture thereof, in particular using biotechnological and genetically-engineered means; process development services in relation to pharmaceutical, veterinary and diagnostic substances; technical consultancy in the pharmaceutical, veterinary and diagnostic sector; services in relation to recombinant protein technology and development.
34.
Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1
Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.
A device for breaking cells that has a reactor with a reaction chamber, an agitator, a cooling jacket, a cooling jacket inlet, a cooling jacket outlet, a sampling port, and a temperature probe insertion fitting, and a motor suitable for mounting the reactor on its top and which is operably connected with the agitator. A system for breaking cells comprising at least one device, at least one temperature probe inserted in the temperature probe insertion fitting of the device, a cooling system operably connected to the temperature probe, and an electronic control panel. The cooling system has at least one solenoid valve, each device of the system having one corresponding solenoid valve.
Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and capture probes, for detection of Plasmodium species nucleic acid in a sample. Also disclosed are methods of specific nucleic acid amplification and detection, including amplification and detection of target nucleic acid in real time, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
C12Q 1/6893 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
Plasmodium Plasmodium species nucleic acid in a sample. Also disclosed are methods of specific nucleic acid amplification and detection, including amplification and detection of target nucleic acid in real time, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
C12Q 1/6893 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Mixing weighing scales to monitor the collection of blood samples. Medical apparatus and instruments, namely blood sample mixers; fixed and portable tube sealing devices for filling blood bags for medical use; devices for the compression of tubes for filling blood bags for medical use.
39.
COMPOSITION COMPRISING RECOMBINANT GpIba RECEPTOR PROTEIN
Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ibα that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.
Various aspects of the invention relate to compositions and methods of analyzing blood plasma, blood serum, and manufacturing pools of plasma-derived products wherein an anionic surfactant is added to an aliquot of the blood plasma, blood serum, or manufacturing pool prior to analysis, and the counterion of the anionic surfactant is not sodium ion. The anionic surfactant may be, for example, lauryl sulfate. The counterion of the anionic surfactant may be, for example, lithium ion.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
41.
IMMUNOASSAYS AND ENGINEERED PROTEINS FOR MONITORING ANTIBODY TREATMENTS TO THE IMMUNE CHECKPOINT INHIBITORS PD1 AND PD-L1
Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.
Systems and methods for guiding the management of blood and/or plasma screening laboratory workflow are disclosed. In some embodiments, a system for analyzing biological samples includes centrifuges, pooling devices, biological sample analyzing devices, and a processor to monitor operation of the centrifuges, the pooling devices, and the biological sample analyzing devices. The processor can track the progress of analysis of the biological samples and generate progress indications via the graphical user interface. In response to determining that an external control is present, the system can prevent release of the biological component to the biological sample analyzing device to perform analysis until the external control is also loaded into the analyzer. In response to a determination that a component of a biological sample is grouped into more than one pool or not intended to be pooled, the system can generate a warning via the graphical user interface. The system can provide a chronology of states, display the status of instruments and biological samples, indicate what components need operator attention, and search and display the status of samples and tests. The system can prevent unintended use, including duplicate testing.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
43.
SYSTEMS AND METHODS FOR BIOLOGICAL SAMPLE LABORATORY SCREENING
Systems and methods for guiding the management of blood and/or plasma screening laboratory workflow are disclosed. In some embodiments, a system for analyzing biological samples includes centrifuges, pooling devices, biological sample analyzing devices, and a processor to monitor operation of the centrifuges, the pooling devices, and the biological sample analyzing devices. The processor can track the progress of analysis of the biological samples and generate progress indications via the graphical user interface. In response to determining that an external control is present, the system can prevent release of the biological component to the biological sample analyzing device to perform analysis until the external control is also loaded into the analyzer. In response to a determination that a component of a biological sample is grouped into more than one pool or not intended to be pooled, the system can generate a warning via the graphical user interface. The system can provide a chronology of states, display the status of instruments and biological samples, indicate what components need operator attention, and search and display the status of samples and tests. The system can prevent unintended use, including duplicate testing.
G01N 1/38 - Diluting, dispersing or mixing samples
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
Various embodiments of the invention relate to polypeptides comprising 1-10 or more epitopes of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks the transmembrane domain of the HIV gp41 protein. Such polypeptides may be expressed in mammalian cells, such as human cells, to produce, for example, polypeptides that are useful in developing novel anti-HIV antibodies. Polypeptides described herein and novel antibodies developed therefrom are generally useful for medical diagnostics, and they may also be useful in the prophylactic and therapeutic treatment of HIV.
Various embodiments of the invention relate to polypeptides comprising 1-10 or more epitopes of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks the transmembrane domain of the HIV gp41 protein. Such polypeptides may be expressed in mammalian cells, such as human cells, to produce, for example, polypeptides that are useful in developing novel anti-HIV antibodies. Polypeptides described herein and novel antibodies developed therefrom are generally useful for medical diagnostics, and they may also be useful in the prophylactic and therapeutic treatment of HIV.
A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies
The invention relates to a device for determining a cellular-bound analyte in a liquid sample, comprising a separation matrix with at least one indicator zone. The invention is characterized in that the indicator zone comprises a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody. The separation matrix is preferably designed in the form of the membrane of a lateral flow assay device or as a gel matrix. In a particularly preferable manner, the device comprises a membrane (2) with a charging zone (5) for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region (3) which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone (5) and the absorption region (3). The invention is characterized in that the indicator zone comprises an antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody.
G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody
G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
G01N 33/559 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody through a gel, e.g. Ouchterlony technique
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemicals used in diagnostics, industry and science; DNA and
RNA preparations for scientific and industrial purposes;
proteins for use within science; chemical reagents for
scientific purposes; diagnostic reagents for scientific
purposes; diagnostic test materials for scientific purposes;
diagnostic agents, preparations and substances for
scientific purposes; assays for research purposes;
biochemical reagents for analyses of nucleic acids,
nucleotides, oligonucleotides, DNA and RNA; chemical
reagents for other than medicinal and veterinary purposes;
biochemical reagents commonly known as probes, for analyses
of genes, nucleotides, oligonucleotides, nucleic acids and
for detecting DNA, RNA and microRNA; biochemical kits
comprising reagents, not for medicinal and veterinary
purposes, for analyses of genes, nucleic acids, nucleotides,
oligonucleotides, DNA, RNA and microRNA. Pharmaceutical, medical and veterinary preparations;
chemico-pharmaceutical preparations; DNA and RNA
preparations for medical and veterinary purposes; biological
preparations for medical and veterinary purposes; chemical
preparations for therapeutic use; reagents for medical
diagnosis and/or analysis; clinical medical reagents;
diagnostic preparations for medical and veterinary purposes;
diagnostic test materials for medical use; diagnostic
agents, preparations and substances for medical use.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemicals used in industry and science; chemicals used in diagnostics, namely, chemical substances for analyses in laboratories other than for medical or veterinary purposes; DNA and RNA diagnostic preparations for scientific and industrial purposes; proteins in raw material form for use within science; chemical reagents for scientific purposes; diagnostic reagents for scientific purposes; diagnostic test materials in the nature of chemical test kits for non-medical DNA testing and PCR based assays for scientific purposes; diagnostic agents, preparations and substances for scientific purposes; assays for research purposes; biochemical reagents for non-medical analyses of nucleic acids, nucleotides, oligonucleotides, DNA and RNA; chemical reagents for other than medicinal and veterinary purposes; biochemical reagents commonly known as probes, for analyses of genes, nucleotides, oligonucleotides, nucleic acids and for detecting DNA, RNA and microRNA for laboratory and research use; biochemical kits comprising reagents, not for medicinal and veterinary purposes, for analyses of genes, nucleic acids, nucleotides, oligonucleotides, DNA, RNA and microRNA Pharmaceutical, medical and veterinary preparations, namely, for treatment, prevention or alleviation of infectious diseases; chemico-pharmaceutical preparations, namely, for treatment, prevention or alleviation of infectious diseases; DNA and RNA diagnostic preparations for medical and veterinary purposes; biological preparations for medical and veterinary purposes, namely, for treatment, prevention or alleviation of infectious diseases; chemical preparations for therapeutic use, namely, for treatment, prevention or alleviation of infectious diseases; reagents for medical diagnosis and/or therapeutic analysis; clinical medical reagents; diagnostic preparations for medical and veterinary purposes; diagnostic test materials, namely, identity tests comprised of reagents, for medical use; diagnostic agents, preparations and substances for medical use
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemicals used in diagnostics, industry and science; DNA and RNA preparations for scientific and industrial purposes; proteins for use within science; chemical reagents for scientific purposes; diagnostic reagents for scientific purposes; diagnostic test materials for scientific purposes; diagnostic kits for scientific purposes; assays for research purposes; biochemical reagents for analyses of nucleic acids, nucleotides, oligonucleotides, DNA and RNA; chemical reagents for other than medicinal and veterinary purposes; biochemical reagents commonly known as probes, for analyses of genes, nucleotides, oligonucleotides, nucleic acids and for detecting DNA, RNA and microRNA; biochemical kits comprising reagents, not for medicinal and veterinary purposes, for analyses of genes, nucleic acids, nucleotides, oligonucleotides, DNA, RNA and microRNA. Pharmaceutical, medical and veterinary preparations; chemico-pharmaceutical preparations; DNA and RNA preparations for medical and veterinary purposes; biological preparations for medical and veterinary purposes; chemical preparations for therapeutic use; reagents for medical diagnosis and/or analysis; clinical medical reagents; diagnostic preparations for medical and veterinary purposes; diagnostic test materials for medical use; diagnostic kits for medical use. Scientific and technological services and research and design relating thereto; industrial analysis and research services; gene research; research and development related to medical and veterinary drugs and preparations, research and development related to biotechnology; research and development related to healthcare; molecular research; development of processes and methods for medical and veterinary purposes; development of preparations for medical and veterinary purposes.
51.
DEVICE AND METHOD FOR DETECTING BLOOD GROUP ANTIGENS BY MEANS OF AN INCOMPLETE ANTIBODY
The invention relates to a device for determining a cellular-bound analyte in a liquid sample, comprising a separation matrix with at least one indicator zone. The invention is characterized in that the indicator zone comprises a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody. The separation matrix is preferably designed in the form of the membrane of a lateral flow assay device or as a gel matrix. In a particularly preferable manner, the device comprises a membrane (2) with a charging zone (5) for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region (3) which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone (5) and the absorption region (3). The invention is characterized in that the indicator zone comprises an antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody.
G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody
G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
[ anti-viral, anti-infective, anti-cancer, anti-psoriatic, and immunoregulatory preparations for human and animal use; storage media for corneas; ] kits comprising chemical reagents for diagnosing medical conditions all for in vitro use [ ; hormones; and peptides ]
